Notice of Change to include NIDA-Specific Interest Areas in PAR-21-281, "Dyadic interpersonal processes and biopsychosocial outcomes (R01, Clinical Trials Not Allowed)"
Notice Number:
NOT-DA-21-072

Key Dates

Release Date:

August 3, 2021

Related Announcements

PAR-21-281 - Dyadic interpersonal processes and biopsychosocial outcomes (R01, Basic Experimental Studies with Humans)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

This Notice informs potential applicants of NIDA-specific interest areas added to PAR-21-281: Dyadic interpersonal processes and biopsychosocial outcomes (R01, Clinical Trials Not Allowed) effective immediately.

The following section of PAR-21-281 have been modified to reflect NIDA-Specific Interest Area language in this FOA:

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

National Institute on Drug Abuse (NIDA)

The National Institute on Drug Abuse (NIDA) supports research that furthers our mission to advance science on the causes and consequences of drug use and addiction, and to apply that knowledge to improve individual and public health. Areas of interest to NIDA under this FOA include, but are not limited to, the following:

  • Determining the neurobiological, chemical or genetic mechanisms by which dyadic interactions affect the substance use trajectory of one or more individuals in the dyad.
  • Innovative basic behavioral research on dyadic processes in couples which may influence substance use including nicotine/tobacco products.
  • Mechanism-based research to identify characteristics of dyadic relationships that enhance or diminish risk for substance use behaviors.
  • Computational modeling of the mechanisms moderating risk-related decision making and substance use behavior (e.g., in peer-peer dyads or parent-adolescent dyads).
  • Parent-child (including mother-infant) dyadic behavior as an outcome or mediator of the impact of maternal or paternal substance use.
  • Determining the causal neurobehavioral mechanisms and the consequent impact of substance use during pregnancy on the mother-infant dyad through animal and/or computational models.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Mary Kautz, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: (301) 443-3206
Email: kautzm@nida.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices